Docetaxel as salvage chemotherapy in advanced gastric cancer patients (AGC): a phase II study of the Southern Italy oncology group (GOIM)

Giuliani, Francesco; Vita, Ferdinando De; Gebbia, Vittorio; Maiello, Evaristo; Catalano, Giuseppe; Gebbia, N.; Colucci, Gianluca

doi:10.1016/s0959-8049(99)81005-3

Cited by 15 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the 36 patients receiving a second-line treatment with docetaxel or irinotecan had a significant better median OS than the 25 patients receiving only best supportive care (12.7 vs 9.4 months; P ¼ 0.0026). These data suggest that salvage chemotherapy in AGC patients progressing after a first-line treatment may have a beneficial impact on survival, as has also been shown in other reports (Ajani et al, 2002;Giuliani et al, 2003). As previously observed in advanced colorectal cancer, in AGC patients, the FOLFOX regimen used in this study demonstrated an acceptable tolerability.…”

Section: Discussionsupporting

confidence: 87%

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

et al. 2005

View full text Add to dashboard Cite

The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks (FOLFOX-4 regimen) in patients with advanced gastric cancer (AGC). A total of 61 previously untreated AGC patients were treated with oxaliplatin 85 mg m À2 on day 1, FA 200 mg m À2 as a 2 h infusion followed by bolus 5-FU 400 mg m À2 and a 22 h infusion of 5-FU 600 mg m À2 , repeated for 2 consecutive days every 2 weeks. All patients were assessable for toxicity and response to treatment. Four (7%) complete responses and 19 partial responses were observed (overall response rate, 38%). Stable disease was observed in 22 (36%) patients, with progressive disease in the other six (10%) patients. Median time to progression (TTP) and median overall survival (OS) were 7.1 and 11.2 months, respectively. National Cancer Institute Common Toxicity Criteria grade 3 and 4 haematologic toxicities were neutropenia, anaemia and thrombocytopenia in 36, 10 and 5% of the patients, respectively. Grade 3 peripheral neuropathy was recorded in three (5%) patients. FOLFOX-4 is an active and well-tolerated chemotherapy. Response rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer.

show abstract

Section: Discussionsupporting

confidence: 87%

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The results of this study seem to be similar or somewhat superior to those achieved with other regimens used in this setting, such as weekly high-dose infusional 5-FU/leucovorin, docetaxel or irinotecan (Futatsuki et al, 1994;Vanhoefer et al, 1994;Graziano et al, 2000;Giuliani et al, 2003). Weekly high-dose infusional 5-FU/leucovorin has been reported to achieve a response rate of 18% and a median overall survival of 5 months (Vanhoefer et al, 1994), whereas docetaxel or irinotecan showed objective response rates in the range of 5 -27% and overall survival times ranging from 3.5 to 10.2 months (Futatsuki et al, 1994;Graziano et al, 2000;Giuliani et al, 2003). However, since our study population was limited to patients with gastric cancer recurrent after previous adjuvant chemotherapy, and excluded those with metastatic advanced gastric cancer who failed first-line chemotherapy, the results of this study should be interpreted cautiously.…”

Section: Discussionsupporting

confidence: 65%

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

Chang

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

To evaluate the efficacy and safety of capecitabine and cisplatin in patients with recurrent gastric cancer after fluoropyrimidine-based adjuvant therapy. Patients with histologically confirmed and measurable advanced gastric cancer that had relapsed after fluoropyrimidine-based adjuvant chemotherapy received oral capecitabine (1250 mg m À2 twice daily, days 1 -14) and intravenous cisplatin (60 mg m À2 over 1 h, day 1) every 3 weeks. In total, 32 patients were enrolled, of whom 30 were evaluable for efficacy and 32 for safety. A median of 5 cycles (range 1 -10) was administered. One patient achieved a complete response and eight had partial responses, giving an overall response rate of 28% (95% CI, 13 -44%). The median time to progression and median overall survival were 5.8 months (95% CI, 4.1 -7.5 months) and 11.2 months (95% CI, 5.5 -16.9 months), respectively. Grade 3 neutropenia and thrombocytopenia were observed in 38 and 6% of patients, respectively. Grade 2/3 nonhaematological toxicities included diarrhoea (19%), stomatitis (19%) and hand-foot syndrome (31%). No grade 4 toxicity, neutropenic fever or treatment-related deaths occurred. Capecitabine in combination with cisplatin was effective and well tolerated as first-line treatment in patients with recurrent gastric cancer after fluoropyrimidine-based adjuvant chemotherapy.

show abstract

“…In these studies, PFS was reported to range between 2.2 and 4.5 months, whereas OS was reported to vary between 3. 5 and 8 months (Graziano et al, 2000;Giuliani et al, 2003;Chun et al, 2004;Cho et al, 2006;Kodera et al, 2007;Jeong et al, 2008;Sym et al, 2008;Baize et al, 2009;Seo et al, 2009;Kim et al, 2010). In our study, PFS was 3.26 months and OS was 8.76 months.…”

Section: Discussionsupporting

confidence: 60%

“…The efficacy of many cytotoxic agents was shown in the first-line therapy. In the second-line therapy, many cytotoxic agents, such as docetaxel, paclitaxel, oxaliplatin, irinotecan, were studied in accordance to the therapy received in the firstline treatment (Kodera et al, 2007;Sym et al, 2008;Giuliani et al, 2003;Seo et al, 2009). Today, there is not a standard therapy for the second-line treatment as well as the first-line treatment.…”

Section: Introductionmentioning

confidence: 99%

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

Küçükzeybek¹,

Dirican²,

Erten³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aim: Tumors of upper gastrointestinal tract are among the cancers that have a quite lethal course. Cytotoxic chemotherapy is the most efficient therapeutic modality for metastatic gastric cancer. In patients who do not respond to first-line treatment, the response rate to second-line therapies is generally low and the toxicity rates high. This study concerned the efficacy and the side effect profile of second-line therapy with irinotecan in the patients who were being followed-up with the diagnosis of metastatic gastric cancer in İzmir, Turkey.

show abstract

Docetaxel as salvage chemotherapy in advanced gastric cancer patients (AGC): a phase II study of the Southern Italy oncology group (GOIM)

Cited by 15 publications

References 0 publications

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

Contact Info

Product

Resources

About